This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
GEHC Stock May Gain as Genesis Portfolio Expands Cloud Offerings
by Zacks Equity Research
GE HealthCare unveils Genesis, a cloud-based imaging portfolio designed to enhance healthcare efficiency, streamline data access, and drive digital transformation.
Here's Why You Should Retain HealthEquity Stock in Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Boston Scientific Gains 42.2% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX's shares rise on the back of its innovative product portfolio and impressive value-added acquisition. However, the unfavorable macroeconomic scenario is concerning.
CAH Stock Up Nearly 7% This Year: Is Now the Time to Buy?
by Zacks Equity Research
CAH continues to grow on the back of its robust product portfolio and a strong quarterly result.
Phibro Animal Health Stock Up 87.5% in a Year: What's Driving the Rise?
by Zacks Equity Research
PAHC stays on investors' radar due to its Animal Health business and potential in emerging markets.
Positive Trial Data on Evolut TAVR Likely to Support MDT Stock
by Zacks Equity Research
At the CRT conference 2025, Medtronic presented two-year favorable SMART trial data, which demonstrated the superior performance of the Evolut TAVR valve in patients with AS.
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge
by Zacks Equity Research
The FTC has blocked GTCR's $627M acquisition of SRDX, citing anti-competitive concerns. Surmodics has responded to the challenge and plans to fight the decision in court.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
by Zacks Equity Research
ECL continues to gain from its robust product portfolio and strong segmental performance.
Stereotaxis Stock Slides Despite MAGiC Sweep Catheter FDA Submission
by Zacks Equity Research
STXS submits MAGiC Sweep, the first robotically navigated high-density EP mapping catheter for FDA clearance, marking a milestone in cardiac arrhythmia treatment.
Cooper Companies Q1 Earnings In Line, Revenues Miss, Stock Falls
by Zacks Equity Research
COO's top line fails to meet market expectations despite recording strong growth. However, improvement in operating margin bodes well.
ALGN Stock Gains on Addition of Upgrades to the iTero Lumina Solutions
by Zacks Equity Research
Align Technology adds restorative capabilities to the iTero Lumina Solutions - the iTero Lumina intraoral scanner and the iTero Lumina Pro dental imaging system.
FMS Stock Gains Following Stake Sale to Reduce Debt & Boost Profit
by Zacks Equity Research
Fresenius Medical Care's parent company sells 10.6 million shares, the proceeds of which will be used to reduce its leverage and achieve higher profits in 2025.
Baxter Stock Likely to Gain Following the Introduction of Voalte Linq
by Zacks Equity Research
At the 2025 HIMSS Global Healthcare Conference, BAX unveils its Voalte Linq device, powered by Scotty assistant, a voice-activated technology.
VEEV Stock Up as Q4 Earnings & Revenues Beat Estimates, Margin Rise
by Zacks Equity Research
Veeva Systems' fiscal fourth-quarter results reflect impressive performance by the Subscription services segment, along with the expansion of gross and operating margins.
Should Labcorp Stock Stay in Your Portfolio Right Now?
by Zacks Equity Research
LH stays on investors' radar owing to its strong focus on high-growth areas and pursuing strategic acquisitions.
SYK Stock Declines Despite Steri-Shield Launch to Boost OR Portfolio
by Zacks Equity Research
Stryker launches Steri-Shield 8, a cutting-edge PPE system with enhanced fit, visibility and protection, reinforcing its leadership in medical safety.
Nevro Q4 Earnings & Revenues Beat Estimates, Gross Margin Down
by Zacks Equity Research
NVRO's fourth-quarter earnings surpass the Zacks Consensus Estimate, while worldwide revenues decline year over year. The company continues to incur losses at the operating level.
Omnicell Gains 41.6% in a Year: What's Driving the Stock?
by Zacks Equity Research
OMCL's shares rise on the back of its XT Amplify program gaining market acceptance with its offerings. However, the unfavorable macroeconomic scenario is concerning.
Here's Why You Should Hold Accuray Stock in Your Portfolio for Now
by Zacks Equity Research
ARAY continues to witness strength in its flagship CyberKnife system, along with robust global performance.
ResMed Stock Climbs 25.6% in a Year: What's Driving the Rally?
by Zacks Equity Research
RMD outperforms the industry and the S&P 500 composite due to its success with the cloud-connected AirSense platform.
SYK Stock Gains on Launch of Hands-Free Device: Sync Badge
by Zacks Equity Research
Stryker's Sunc Badge is a Hands-free, wearable communication device that will support care team members with fast and reliable collaboration. It is likely to help offset the ongoing nurse shortage.
STXS Stock Tumbles Despite EMAGIN Catheter Submission for Approval
by Zacks Equity Research
Stereotaxis submits EMAGIN 5F, a robotic catheter, for regulatory clearance.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Masimo Corporation (MASI) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Masimo (MASI) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
TECH Joins Forces With Oxford Nanopore Technologies: Stock to Gain?
by Zacks Equity Research
Bio-Techne's Asuragen brand inks a partnership with Oxford Nanopore Technologies to launch research-use-only AmplideX Nanopore Carrier Plus Kit.